caa a22 4500 465736998 CHVBK 20180323111757.0 cr unu---uuuuu 170327e19900901xx s 000 0 eng 10.1007/BF02245751 doi (NATIONALLICENCE)springer-10.1007/BF02245751 Characterisation of the phenomenon of "one-trial tolerance” to the anxiolytic effect of chlordiazepoxide in the elevated plus-maze [Elektronische Daten] [Sandra File, Peter Mabbutt, Paul Hitchcott] In the elevated plus-maze test of anxiety the scores of control animals remain stable over repeated tests. However, a single prior exposure to the plus-maze renders an animal insensitive to the anxiolytic effects of chlordiazepoxide. This phenomenon of "one-trial tolerance” persisted even when the two trials were separated by as much as 2 weeks. It has previously been shown that the drug state of the animal on trial 1 is not important to the development of the phenomenon, but one-trial tolerance did not develop if a very high dose (75 mg/kg) of chlordiazepoxide was given on trial 1; it is suggested that this is due to the amnesic effects of the drug. The learning on trial 1 was not specific to a particular plus-maze and tolerance could be observed even when the maze on trial 1 was made from different material. The crucial experience on trial 1 was experience of an open arm of the maze. Whereas tolerance could be obtained as a result of a previous plus-maze experience, there was no evidence of an anxiogenic withdrawal response when rats were tested the following day undrugged. The phenomenon of one-trial tolerance is explained within our recently proposed two-factor theory of benzodiazepine dependence; it is suggested that one-trial tolerance provides a method for studying the mechanism underlying the development of tolerance to anxiolytic effects, independently from the mechanism underlying the development of withdrawal responses. Springer-Verlag, 1990 Benzodiazepines nationallicence Tolerance nationallicence Learning nationallicence Benzodiazepine dependence nationallicence File Sandra Psychopharmacology Research Unit, UMDS Division of Pharmacology, University of London, Guy's Hospital, SE1 9RT, London, UK aut Mabbutt Peter Psychopharmacology Research Unit, UMDS Division of Pharmacology, University of London, Guy's Hospital, SE1 9RT, London, UK aut Hitchcott Paul Psychopharmacology Research Unit, UMDS Division of Pharmacology, University of London, Guy's Hospital, SE1 9RT, London, UK aut Psychopharmacology Springer-Verlag 102/1(1990-09-01), 98-101 0033-3158 102:1<98 1990 102 213 https://doi.org/10.1007/BF02245751 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF02245751 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- File Sandra Psychopharmacology Research Unit, UMDS Division of Pharmacology, University of London, Guy's Hospital, SE1 9RT, London, UK aut NATIONALLICENCE 700 1- Mabbutt Peter Psychopharmacology Research Unit, UMDS Division of Pharmacology, University of London, Guy's Hospital, SE1 9RT, London, UK aut NATIONALLICENCE 700 1- Hitchcott Paul Psychopharmacology Research Unit, UMDS Division of Pharmacology, University of London, Guy's Hospital, SE1 9RT, London, UK aut NATIONALLICENCE 773 0- Psychopharmacology Springer-Verlag 102/1(1990-09-01), 98-101 0033-3158 102:1<98 1990 102 213 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer